September 22 is International CML Awareness Day.
In 2008, the CML Society of Canada came up with a great idea. What if there were a
special day to raise awareness about all the wonderful discoveries that took place
that drastically changed the course of Chronic Myelogenous Leukemia, this once
always nearly fatal disease.
CML is a slowly progressing cancer of the blood and bone marrow. It is characterized
by an overproduction of white blood cells which do not mature, ultimately
cannot carry out their intended function and crowd out the healthy cells.
The mission of the CML Society is to help reduce suffering and improve care and
the quality of life of CML patients.
LifeScience Moment: The Hatch-Waxman Act was passed to encourage development of generic prescription drugs."
On September 24, 1984 the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act) was passed to encourage development of
generic prescription drugs.
The Act, named for its sponsors, Representative Henry Waxman of California and Senator Orrin Hatch of Utah, established a process
whereby marketers of generic drugs can file Abbreviated New Drug Applications (ANDAs) to seek FDA approval of the generic; allows 180 day
exclusivity to companies that are the "first-to-file" an ANDA against holders of patents for branded counterparts; and streamlined the process
for approving generic drugs by requiring only that manufacturers demonstrate "bioequivalence" to an already approved innovator drug.
It's a Small World
Anthrax Bacteria (Photo Credit: Janice Haney Carr)
"It is a popular delusion that the scientific enquirer is under an obligation not to go beyond generalisation of observed facts...but anyone who is practically acquainted with scientific work is aware that those who refuse to go beyond the facts, rarely get as far."
Thomas H. Huxley, English biologist